A report from the 2017 meeting of the American Diabetic Association
Hypogonadal men with type 2 diabetes (T2D) who were treated with testosterone undecanoate (TU) injections demonstrated reductions in glycated hemoglobin A1c (HbA1c). The study included 321 men with hypogonadism in a urological setting. Of these men, 94 (29.3%) had T2D and were treated with the TU injections for up to 12 years. Results obtained during the final observation revealed that 90.4% of patients were within an HbA1c target of <7%, and 78.7% were within an HbA1c target of <6.5%. In addition, the following metrics were also reduced from baseline: fasting glucose, weight, waist circumference, and body mass index.
Dr Saad said that for men with hypogonadism and obesity as well as type 2 diabetes, adequate testosterone therapy may be the most beneficial treatment possible. “The unique effect of testosterone is that it invariably increases lean body mass, which helps normalize metabolism,” he said. “This cannot be achieved with any other drug.”
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
